2. Induced Disease Models Products Protein Tyrosine Kinase/RTK Metabolic Enzyme/Protease
  3. Immunology and Inflammatory Disease Models Digestive System Disease Models VEGFR Endogenous Metabolite
  4. Pancreatitis Models Pancreatic Disease Models
  5. Taurocholic acid sodium

Taurocholic acid sodium  (Synonyms: Sodium taurocholate; N-Choloyltaurine sodium)

Cat. No.: HY-N0545 Purity: 99.82%
COA
SDS
Handling Instructions Technical Support

Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect.

For research use only. We do not sell to patients.

CAS No. : 145-42-6

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
500 mg In-stock
1 g In-stock
5 g In-stock
10 g   Get quote  
50 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 31 publication(s) in Google Scholar

Other Forms of Taurocholic acid sodium:

Taurocholic acid sodium Related Antibodies

Top Publications Citing Use of Products

31 Publications Citing Use of MCE Taurocholic acid sodium

In Vivo Efficacy Study
WB
ELISA
Histological Imaging/Staining
IF
RT-PCR

    Taurocholic acid sodium purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Feb 3:e2411719.  [Abstract]

    The mRNA levels of ALDOB in Huh7 or HCCLM3 cells treated with various bile acids (100 μM, 24 h). All data are presented as mean ± SD. Data were analyzed by one-way ANOVA with Bonferroni multiple-comparison correction. CA, cholic acid; TCA, taurocholic acid; GCA, glycocholic acid; TCDCA, taurochenodeoxycholic acid; GCDCA, glycochenodeoxycholic acid; LCA, lithocholic acid; TLCA, taurolithocholic acid; GLCA, glycolithocholic acid; DCA, deoxycholic acid; TDCA, taurodeoxycholic acid; GDCA, glycodeoxycholic acid; UDCA, ursodeoxycholic acid; TUDCA, tauroursodeoxycholic acid; GUDCA, glycoursodeoxycholic acid.

    Taurocholic acid sodium purchased from MedChemExpress. Usage Cited in: Nature. 2025 Jul;643(8070):192-200.

    Taurocholic acid (TCA, 100 μM, 4 h) activated AMPK depending on the cAMP–Epac–MEK pathway in primary hepatocytes.

    Taurocholic acid sodium purchased from MedChemExpress. Usage Cited in: Food Funct. 2024 May 7;15(9):5088-5102.

    Taurocholic acid (TCA, infused into the PVN at 10 μg per day for 28 days) reduced systolic blood pressure in spontaneously hypertensive rats.

    Taurocholic acid sodium purchased from MedChemExpress. Usage Cited in: Food Funct. 2024 May 7;15(9):5088-5102.

    Taurocholic acid (TCA, infused into the PVN at 10 μg per day for 28 days) reduced plasma levels of norepinephrine in spontaneously hypertensive rats.

    Taurocholic acid sodium purchased from MedChemExpress. Usage Cited in: Food Funct. 2024 May 7;15(9):5088-5102.

    Taurocholic acid (TCA, infused into the PVN at 10 μg per day for 28 days) reduced cardiomyocyte dilation (A-B) and fibrosis (C-D) in spontaneously hypertensive rats.

    Taurocholic acid sodium purchased from MedChemExpress. Usage Cited in: Food Funct. 2024 May 7;15(9):5088-5102.

    Taurocholic acid (TCA, infused into the PVN at 10 μg per day for 28 days) reduced the average fluorescence intensity of DHE in cardiomyocytes of spontaneously hypertensive rats.

    View All VEGFR Isoform Specific Products:

    View All Isoforms
    VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

    View All Endogenous Metabolite Isoform Specific Products:

    View All Isoforms
    Human Endogenous Metabolite Microbial Metabolite

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect[1].

    IC50 & Target

    Microbial Metabolite

     

    Human Endogenous Metabolite

     

    In Vitro

    Taurocholic acid (100 μM, 24 h) sodium decreases the proportion of CD3+CD8+ T and NK cells in isolated PBMCs from HBeAg-positive CHB patients[2].
    Taurocholic acid (100 μM, 24 h) sodium decreases IFN-α stimulated cytokine and cytotoxic granule levels (IFN-γ, TNF-α, granzyme B) in CD3+CD8+ T and NK cells[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Taurocholic acid sodium Related Antibodies
    In Vivo

    Taurocholic acid (oral gavage, 100 mg/kg, 2 weeks) sodium promotes HBV replication by reducing the percentage of NK and CD3+CD8+ T cells in C57BL/6 mice with tail vein injection with rAAV8-1.3HBV[2].
    Taurocholic acid (1% in diet, 1 week) sodium prevents hepatic artery ligation (HAL)-induced cholangiocyte damage in rats by upregulation of VEGF-A expression[3].

    Note:
    Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

    Taurocholic acid can be used in animal modeling to create stress-induced gastric injury models and pancreatitis models[3][4][5].

    1. Induction of stress-induced gastric injury[3]
    Background
    Both in humans and experimental animals, Taurocholic acid irritates the gastric mucosa and causes the reverse diffusion of acid through the broken barrier.
    Specific Modeling Methods
    Rat: Donryu strain rats • male • 230-240 g &bull
    Administration: 30-300 mg/kg • p.o • single dose.
    Note
    After rats have fasted for 24 hours, their pylorus is ligated under ether anesthesia. Fifteen minutes after pylorus ligation, medication is administered to the rats.
    The pylorus-ligated rats are then placed in cages with restricted movement.
    Subsequently, the cages are immersed in a water bath maintained at 23°C until the water level reaches the xiphoid process of the rats, lasting for 7 hours.
    Seven hours later, the animals are sacrificed under ether anesthesia, and the stomach of each animal is removed. The gastric contents are collected through the esophagus and analyzed for volume and acidity.
    Modeling Indicators
    Molecular Changes: Significant reductions in acidity and pepsin activity were observed, along with an increase in Na+ concentration. However, there was no effect on gastric juice volume or K+ concentration.
    Correlated Product(s): Aspirin (HY-14654)
    Opposite Product(s): L-Glutamine (HY-N0390)

    2. Induction of Acute Pancreatitis[4].
    Background
    Taurocholic acid induced the formation of interstitial edema and caused acinar cell vacuolization in the pancreatic lobules. Taurocholic acid also increased serum amylase and lipase activities. Interstitial edema becomes one of the most important criteria for assessing pancreatic damage in acute pancreatitis[4].
    Specific Modeling Methods
    Rat: Wistar• male • weighing 220-240 g[1]
    Administration: 1 mL/kg• retrograde infusion into the common pancreaticobiliary duct• at a speed of 0.25 mL/min[4]
    Mice: Balb/c and Wistar• male • weighing 25-30 g and 250-300 g[5]
    Administration: 1 mL/kg• retrograde infusion• perfusion for 8 h[5]
    Note
    (1) Before administration, mice were kept at room temperature of 23±1°C and 50-60 % relative humidity with free access to water and chow on a 12-h light/dark cycle. They were allowed to adapt to this environment for 5 days before the experiment, and received no nourishment and free access to water for 12 h preoperatively[1][2].
    (2) Pancreatic acinar cells were isolated freshly from Balb/c or C57/BL6J mice using a collagenase IV. Cells were treated under room temperature, and used within 4 hours after isolation[2].
    Modeling Indicators
    b>Histological analysis: Taurocholic acid administration caused the formation of interstitial edema in the pancreas and an increase of pancreas weight. Acinar cell vacuolization was evident in the pancreatic lobules, accompanied by some foci of pancreatic hemorrhage and marked peritoneal ascites. A pyknotic nucleus was in the center of necrotic acinar cell with a bright border. Taurocholic acid administration induced marked oedema, inflammatory cell infiltration and acinar cell necrosis[1][2].
    Biochemical Analysis: Taurocholic acid administration increased serum amylase and lipase activities[1].
    Correlated Product(s): Neuronostatin; Flavonoids 1

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: C57BL/6 mice[2]
    Dosage: 100 mg/kg
    Administration: oral gavage, for 2 weeks after tail vein injection with rAAV8-1.3HBV for 6 weeks
    Result: Reduced the percentage of NK and CD3+CD8+ T cells.
    Increases serum HBsAg, HBeAg, and HBV DNA levels.
    Molecular Weight

    537.68

    Formula

    C26H44NNaO7S
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    C[C@H](CCC(NCCS(=O)(O[Na])=O)=O)[C@H]1CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C
    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    -20°C, sealed storage, away from moisture

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 100 mg/mL (185.98 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    H2O : 100 mg/mL (185.98 mM; Need ultrasonic)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.8598 mL 9.2992 mL 18.5984 mL
    5 mM 0.3720 mL 1.8598 mL 3.7197 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 5 mg/mL (9.30 mM); Clear solution

      This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

    • Protocol 2

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (4.65 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
    Purity & Documentation

    Purity: 99.82%

    SDS (394 KB)

    COA (250 KB) HNMR (301 KB) RP-HPLC (234 KB) MS (69 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO / H2O 1 mM 1.8598 mL 9.2992 mL 18.5984 mL 46.4961 mL
    5 mM 0.3720 mL 1.8598 mL 3.7197 mL 9.2992 mL
    10 mM 0.1860 mL 0.9299 mL 1.8598 mL 4.6496 mL
    15 mM 0.1240 mL 0.6199 mL 1.2399 mL 3.0997 mL
    20 mM 0.0930 mL 0.4650 mL 0.9299 mL 2.3248 mL
    25 mM 0.0744 mL 0.3720 mL 0.7439 mL 1.8598 mL
    30 mM 0.0620 mL 0.3100 mL 0.6199 mL 1.5499 mL
    40 mM 0.0465 mL 0.2325 mL 0.4650 mL 1.1624 mL
    50 mM 0.0372 mL 0.1860 mL 0.3720 mL 0.9299 mL
    60 mM 0.0310 mL 0.1550 mL 0.3100 mL 0.7749 mL
    80 mM 0.0232 mL 0.1162 mL 0.2325 mL 0.5812 mL
    100 mM 0.0186 mL 0.0930 mL 0.1860 mL 0.4650 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Taurocholic acid sodium Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Taurocholic acid145-42-6Sodium taurocholateN-CholoyltaurineVEGFREndogenous MetaboliteVascular endothelial growth factor receptorhepatic arteryVEGF-A expressionliver cirrhosisImmunoregulationTumor necrosis factor-αInterleukin-1βCD4+/CD8+Inhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Taurocholic acid sodium
    Cat. No.:
    HY-N0545
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (394 KB) Français - FR (394 KB) Deutsch - DE (394 KB) Norwegian - NO (394 KB) Español - ES (394 KB) Swedish - SV (394 KB) Italian - IT (394 KB) Korean - KR (394 KB) Portuguese - PT (394 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.